Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVYXFK)

Drug Name

TAK-755 Drug Info

Synonyms

ADAMTS13

Indication

Disease Entry	ICD 11	Status	REF
Congenital thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[1]
Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13)	TTUREBK	ATS13_HUMAN	Replacement	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05770219) Expanded Access Program: TAK-755 (rADAMTS13) for the Prophylaxis and Treatment of Severe Congenital or Hereditary Thrombotic Thrombocytopenic Purpura. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT03393975) A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]). U.S.National Institutes of Health.
3	Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica. 2022 Nov 1;107(11):2650-2660.